Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

EVO - Evotec SE Последние новости | Finranks

Home

EVO

E

Evotec SE (EVO)

NMS – Цена в реальном времени. Валюта: USD

2.42

-0.04 (-1.63%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

2.42

-0.00 (-0.21%)

После закрытия: Mar 27, 2026, 4:04 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses

Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses

The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yields Manufacturing process development strengthens U.S. government response capabilities against hemorrhagic fever outbreaks caused by Ebola and Sudan virus HAMBURG, DE / ACCESS Newswire / March 23, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced its Seattle-based subsidiary and CDMO, Just - Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV). The multi-year program award, valued at up to $10 m if all options are activated, will support BARDA's efforts to strengthen national preparedness by supporting the development of cost‑effective medical countermeasures that can augment the U.S. government's response capabilities with therapeutics targeting filovirus diseases.

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment in strategic protein degradation collaboration with Bristol Myers Squibb (BMS) aiming to establish new treatment paradigm in advanced clear cell renal cell carcinoma Study start highlights transition into the clinic for Evotec-BMS oncology platform and reflects robust pipeline of ‘molecular glues' being advanced as treatment options for different cancer types Validates Evotec's high-performance multi-omics screening and AI-supported data analytics and drug design capabilities HAMBURG, DE / ACCESS Newswire / March 19, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that its partner Bristol Myers Squibb (BMS) has initiated a Phase 1 clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer. Initiation of the first‑in‑human study represents a significant advancement in the strategic protein degradation collaboration, bringing into the clinic a novel CELMoD or ‘molecular glue' candidate jointly generated through Evotec's powerful and fully integrated drug discovery platform.

Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Evotec SE (NASDAQ: EVO). The investigation focuses on Evotec executive officers and whether investor losses may be recovered under federal securities laws.

Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript

Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript

Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript

Evotec Restructuring Aims To Improve Profitability After Transition Year

Evotec Restructuring Aims To Improve Profitability After Transition Year

Evotec SE (NASDAQ: EVO) stock is trading lower on Tuesday.

Evotec: What's Going On In 2026E And How To Value The Company

Evotec: What's Going On In 2026E And How To Value The Company

Evotec is rated a speculative "Buy" with a reduced price target of $9/share (Nasdaq), reflecting delayed profitability and execution risks. Recent results showed revenues near the upper end of guidance (€790 million), but EBITDA and core D&PD performance remain challenged by persistent high costs. Multiple transformation plans, including the new "Horizon," have yet to restore investor confidence, with profitability now expected only by 2028E.

Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity, and stability, over the next three years HAMBURG, DE / ACCESS Newswire / January 8, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announces that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just - Evotec Biologics' molecular design suite of computational technologies, called "J.MD™". Investment (INV072135) continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of goods of monoclonal antibodies to make them more affordable and accessible and prevent infectious disease in low- and middle-income countries.

Видео

No Data

There is no data to display

Пресс-релизы

Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses

Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses

The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yields Manufacturing process development strengthens U.S. government response capabilities against hemorrhagic fever outbreaks caused by Ebola and Sudan virus HAMBURG, DE / ACCESS Newswire / March 23, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced its Seattle-based subsidiary and CDMO, Just - Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV). The multi-year program award, valued at up to $10 m if all options are activated, will support BARDA's efforts to strengthen national preparedness by supporting the development of cost‑effective medical countermeasures that can augment the U.S. government's response capabilities with therapeutics targeting filovirus diseases.

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment in strategic protein degradation collaboration with Bristol Myers Squibb (BMS) aiming to establish new treatment paradigm in advanced clear cell renal cell carcinoma Study start highlights transition into the clinic for Evotec-BMS oncology platform and reflects robust pipeline of ‘molecular glues' being advanced as treatment options for different cancer types Validates Evotec's high-performance multi-omics screening and AI-supported data analytics and drug design capabilities HAMBURG, DE / ACCESS Newswire / March 19, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that its partner Bristol Myers Squibb (BMS) has initiated a Phase 1 clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer. Initiation of the first‑in‑human study represents a significant advancement in the strategic protein degradation collaboration, bringing into the clinic a novel CELMoD or ‘molecular glue' candidate jointly generated through Evotec's powerful and fully integrated drug discovery platform.

Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Evotec SE (NASDAQ: EVO). The investigation focuses on Evotec executive officers and whether investor losses may be recovered under federal securities laws.

Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity, and stability, over the next three years HAMBURG, DE / ACCESS Newswire / January 8, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announces that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just - Evotec Biologics' molecular design suite of computational technologies, called "J.MD™". Investment (INV072135) continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of goods of monoclonal antibodies to make them more affordable and accessible and prevent infectious disease in low- and middle-income countries.